Coloradans are facing a silent but deadly threat, and it's hiding in plain sight: the alarming rise of counterfeit weight-loss drugs. But here's where it gets controversial—while legitimate GLP-1 medications have revolutionized obesity treatment, a shadowy gray market is exploiting this progress, putting lives at risk. As a physician assistant who has dedicated my career to patient care, I’ve seen firsthand how these therapies, when used properly, can transform lives. Yet, the surge in demand has unleashed a wave of unscrupulous actors peddling unapproved, potentially dangerous alternatives that bypass critical safety measures.
Let’s be clear: Colorado families deserve better. Earlier this year, Governor Jared Polis signed legislation expanding access to weight-loss treatments, including GLP-1 medications, a move that could benefit the over 24% of Colorado adults affected by obesity. When used under medical supervision, these drugs offer a dignified path to better health. But this is the part most people miss—the gray market has turned a lifeline into a gamble. Compounding pharmacies, med-spas, and even telehealth companies are sourcing active pharmaceutical ingredients (APIs) from unregulated foreign suppliers, creating products that lack FDA approval and the rigorous safety standards patients trust.
What’s even more alarming? Some companies are selling raw APIs directly to consumers, essentially turning complex medications into DIY projects. Imagine self-administering a drug that affects your metabolism and hormones without knowing its purity or dosage—it’s not just risky; it’s reckless. As of July 2025, federal data reveals hundreds of adverse events linked to these illicit products, including hospitalizations and deaths. These aren’t just numbers; they’re lives shattered by a system that failed to protect them.
The crisis began with legitimate shortages, prompting compounding pharmacies to step in as a temporary solution. But long after the shortages ended, the gray market persisted, fueled by profit over patient safety. Now, it’s up to federal and state leaders to act. The federal government must tighten enforcement to block illicit APIs from entering U.S. supply chains, as Attorney General Phil Weiser and Colorado’s congressional delegation have urged. Meanwhile, Colorado’s regulators and legislators need to crack down on illegal compounders, hold bad actors accountable, and ensure only FDA-regulated medications reach patients.
Here’s the bold question I’m posing to you: Should we prioritize profit over patient safety, or demand transparency and accountability in our healthcare system? As a clinician and a Coloradan, I believe everyone deserves access to safe, effective treatments—not dangerous shortcuts. If our leaders rise to this challenge, we can ensure that obesity treatments remain tools of healing, not hazards in disguise. What do you think? Let’s start the conversation.
